The CAIRO5 trial confirmed the benefit of both two-drug chemotherapy regimens with bevacizumab instead of a three-drug ...

The study highlights how EV-DNA packaging influences immune responses and its promise as a biomarker for assessing colorectal ...

Growing demand for sophisticated and personalized treatment options to cure liver metastasis is expected to boost the market.Rockville, MD, Dec. 10, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a ...

MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...

Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell ...

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

Using laboratory mice with metastatic lung and liver tumors, human colorectal cancer tissue, and 3D colorectal cancer tumor ...

Contrary to expectations, higher levels of this EV-DNA reduced liver metastasis risks in pancreatic and colorectal cancers.

About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...